RCS - Verici Dx PLC - Non-executive Director receives award

Verici DxAnnouncement

24/06/2021 07:05

RNS Number : 9050C
  
Verici Dx PLC
  
24 June 2021
  
 

Verici Dx plc
("Verici Dx" or the "the Company") 
 
Dr Barbara T. Murphy to receive

The American Society of Nephrology Lifetime Achievement Award
 
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, would like to congratulate Dr Barbara T. Murphy M.B. B.A.O. B.Ch., FRCPI, Non-Executive Director of Verici Dx, upon her award for a new Lifetime Achievement Award from the American Society of Nephrology ('ASN') to recognise trailblazers in the branch of medicine that deal with the physiology and diseases of the kidneys. ASN will present the award to Barbara T. Murphy, in recognition of her extraordinary contributions to patient care, research, and education as well as through her advocacy, creativity, entrepreneurialism, leadership, and community service.
 
Susan E. Quaggin, MD, FASN, President at American Society of Nephrology, commented: "Dr. Murphy is a true trailblazer who has elevated our profession by transforming the delivery of and improving access to care, developing new areas of academic pursuit, opening innovative avenues of investigation and academic thought, serving as a role model, and influencing disruptive and positive change. With this award, ASN seeks to recognize leaders like Dr. Murphy who embody the principles of the society and have the courage to forge new paths, overcome challenges, and serve as exemplars for future generations of nephrologists to admire, emulate, and amplify."
 
Dr. Murphy is the Murray M. Rosenberg Professor of Medicine, chair of the Department of Medicine for Mount Sinai and Dean for Clinical Integration and Population Health. Her area of interest is transplant immunology, focusing on the use of high throughput genomic technologies as a means to understand the immune mechanisms that lead to graft injury and loss, with the aim of identifying gene expression profiles and or genetic variants that may be used to predict those at greatest risk.
 
Dr. Murphy earned her M.B. B.A.O. B.Ch. from The Royal College of Surgeons in Ireland and went on to do an internship at Beaumont Hospital in Dublin. She completed a residency rotation at Beaumont Hospital followed by a fellowship in Clinical Nephrology also at Beaumont Hospital. Dr. Murphy completed her postdoctoral training with a fellowship in Nephrology at Brigham and Women's Hospital, Harvard Medical School. As part of this she trained in transplant immunology at the Laboratory of Immunogenetics and Transplantation, Renal Division, Brigham and Women's Hospital, Harvard Medical School. Among her many honours, Dr. Murphy was awarded the Young Investigator Award in Basic Science by the American Society of Transplantation in 2003. In 2005, Dr. Murphy was awarded the Irene and Dr. Arthur M. Fishberg Professor of Medicine at The Mount Sinai Hospital. Then, in 2011, she was named Nephrologist of the Year by the American Kidney Fund. She received the distinguished Jacobi Medallion in 2014. She also received an honorary degree from University College, Dublin, Ireland. In 2016, Dr. Murphy was honoured by The Annual Irish America Healthcare & Life Science 50.
 
Dr. Murphy belongs to a number of professional societies including the American Society of Transplantation and the American Society of Nephrology. Among her numerous achievements, she has held many leadership roles at a national level, including being a member of the board of the American Society of Transplantation, the executive committee of the American Transplant Congress, and chair of Education Committee of the American Society of Transplantation. In 2009 Dr. Murphy was the president of the American Society of Transplantation and in 2016 was elected to council for the American Society of Nephrology.
 
 
 
Enquiries:
 



Verici Dx


 




Sara Barrington, CEO 


Via Walbrook PR




Julian Baines, Chairman


 








 




N+1 Singer (Nominated Adviser & Broker)


Tel: 020 7496 3000




Aubrey Powell / Justin McKeegan / Tom Salvesen 


 








 




Walbrook PR Limited
 



vericidx@walbrookpr.com




Paul McManus / Sam Allen


Tel: 020 7933 8780
Mob: 07980 541 893 / 077502 558 258



 
 
About Verici Dx plc www.vericidx.com


Verici Dx is developing and commercialising tests to understand how a patient will and is responding to organ transplant, with an initial focus on kidney transplants. The body's own immune system poses a threat to a successful transplant or graft. Patients' immune systems differ in how they respond to the presence of the transplanted organ, characterising this response is called immune phenotyping. Our products and solutions are underpinned by extensive scientific research into the recipient's immune phenotype and how that impacts on acute rejection, chronic injury and ultimately failure of the transplant. These immuno-profile signatures also inform clinicians as to the optimal strategy for immunosuppressive and other therapies for the most successful treatment to ensure graft acceptance with the least amount of side effects.
 
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NRAUORNRAKUNUAR